ASCO GUIDELINES Bundle

Osteoporosis in Survivors of Adult Cancers with Non-Metastatic Disease

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475491

Contents of this Issue

Navigation

Page 9 of 9

Disclaimer is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y Guideline. is resource is a practice tool based on ASCO ® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. is pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are available at www.asco.org/hematologic-malignancies-guidelines. Copyright ©2019 by American Society of Clinical Oncolog y. All rights reserved. Source Shapiro CL, Lacchetti C, Neuner J. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline Summary. Journal of Oncology Practice. September 2019. doi:10.1200/jop.19.00427. 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2019 All rights reserved. ASCOOST1993 ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Additional information, which may include data supplements, slide sets, and other clinical tools and resources, is available at www.asco.org/survivorship-guidelines. Abbreviations AI, aromatase inhibitor; ADT, androgen deprivation therapy; BMD, bone mineral density; CIOF, chemotherapy-induced ovarian failure; DXA, dual X-ray absorptiometry; GnRH, gonadotropin releasing hormones; IV, intravenous; MRONJ, medication-related osteonecrosis of the jaw; SQ, subcutaneous Recommendation Grading Type Benefit/harm Evidence Quality Strength of Recommendation EB Evidence- based B Benefits outweigh harms H High Strong EP Expert panel H Harms outweigh benefits I Intermediate Moderate IC Informal consensus B/H Relative balance of benefits and harms L Low Weak Ins Insufficient

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Osteoporosis in Survivors of Adult Cancers with Non-Metastatic Disease